Clinical response to futibatinib in intrahepatic cholangiocarcinoma with acquired resistance to fibroblast growth factor receptor 2 inhibitors

被引：0
|
作者：
Casalino, S. [1 ]
Gerdes, C. [2 ]
Saborowski, A. [2 ]
Quinzii, A. [1 ]
Zecchetto, C. [1 ]
Sordo, A. [3 ]
Messineo, L. [1 ]
Leta, L. C. [1 ]
Lucin, E. [1 ]
Mendo, L. [1 ]
Pietrobono, S. [1 ]
Vogel, A. [4 ]
Melisi, D. [1 ]
机构：
[1] Univ Verona, Digest Mol Clin Oncol Res Unit, Verona, Italy
[2] MHH, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[3] Univ Padua, Unit Biostat Epidemiol & Publ Hlth, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy
[4] Princess Margaret Canc Ctr, Div Gastroenterol & Hepatol, Toronto, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.447
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
304P
引用
收藏
页码：S128 / S129
页数：2
相关论文
共 50 条
  • [21] Durable response from fibroblast growth factor receptor inhibition in intrahepatic cholangiocarcinoma terminated by metachronous acute myeloid leukemia: a case report
    Andreas Edwin Juarso
    Stefanie Entz
    Florian Weissinger
    Journal of Medical Case Reports, 17
  • [22] Fibroblast growth factor receptors as a potential therapeutic target in patients with intrahepatic cholangiocarcinoma
    Morizane, Chigusa
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma
    Ilyas, Sumera I.
    Yamada, Daisaku
    Hirsova, Petra
    Bronk, Steven F.
    Werneburg, Nathan W.
    Krishnan, Anuradha
    Salim, Warda
    Zhang, Liang
    Trushina, Eugenia
    Truty, Mark J.
    Gores, Gregory J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (15) : 8031 - 8047
  • [24] A NEW ERA OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITION IN CHOLANGIOCARCINOMA
    Lamarca, A.
    Moreno, V.
    Gambardella, V.
    Cervantes, A.
    ESMO OPEN, 2023, 8 (06)
  • [25] Pemigatinib Fibroblast growth factor receptor inhibitor Treatment of cholangiocarcinoma
    Franco, B.
    Clarke, P.
    Carotenuto, P.
    DRUGS OF THE FUTURE, 2019, 44 (12) : 923 - 932
  • [26] Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma (vol 51, pg 911, 2021)
    Tsujie, Masanori
    Iwai, Tomohisa
    Kubo, Shoji
    Ura, Takashi
    Hatano, Etsuro
    Sakai, Daisuke
    Takeda, Yutaka
    Kaibori, Masaki
    Kobayashi, Tomoe
    Katanuma, Akio
    Katayose, Yu
    Fukase, Koji
    Sakurai, Naoki
    Ito, Yukiko
    Sato, Fumiya
    Maeda, Atsuyuki
    Asada, Masanori
    Morizane, Chigusa
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (11) : 1694 - 1694
  • [27] Genetic determinants of response to fibroblast growth factor receptor inhibitors in solid tumours
    Leroy, Laura
    Cousin, Sophie
    Italiano, Antoine
    EUROPEAN JOURNAL OF CANCER, 2017, 81 : 102 - 105
  • [28] Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
    Bensi, M.
    Giannarelli, D.
    Bagala, C.
    Niger, M.
    Bergamo, F.
    Barone, D.
    Rizzato, M. D.
    Nichetti, F.
    Spring, A.
    De Rosa, A.
    Beccia, V.
    Ricagno, G.
    Pircher, C. C.
    Ardito, F.
    Barbaro, B.
    Giuliante, F.
    Martinelli, E.
    De Braud, F. G. M.
    Lonardi, S.
    Tortora, G.
    Salvatore, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S229 - S229
  • [29] Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma
    Yang, Xiao-Qing
    Xu, Yun-Fei
    Guo, Sen
    Liu, Yi
    Ning, Shang-Lei
    Lu, Xiao-Fei
    Yang, Hui
    Chen, Yu-Xin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (14) : 4076 - 4084
  • [30] Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma
    Xiao-Qing Yang
    Yun-Fei Xu
    Sen Guo
    Yi Liu
    Shang-Lei Ning
    Xiao-Fei Lu
    Hui Yang
    Yu-Xin Chen
    World Journal of Gastroenterology, 2014, (14) : 4076 - 4084
12345